Moclobemide overdose

  title={Moclobemide overdose},
  author={P. Myrenfors and T. Eriksson and C. Sandstedt and G. Sj{\"o}berg},
  journal={Journal of Internal Medicine},
Abstract. Moclobemide is a recently introduced short‐acting, selective and reversible monoamine oxidase inhibitor, type A, with few and mild side‐effects at therapeutic doses. Fifteen reported cases of moclobemide overdose were studied in detail and are presented here. While pure mechanism overdosage seems benign, a combination with tricyclic antidepressants may result in serious poisoning even when the moclobemide overdose is modest. 


Moclobemide, a new reversible MAO inhibitor — interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients
In conclusion, moclobemide appears relatively safe with respect to tyramine sensitivity and interaction with tricyclics. Expand
Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
It is concluded that tyramine in quantities of up to 100 mg does not lead to clinically relevant blood pressure reactions in moclobemide-treated subjects, if moclopemide is taken at the end of the meal. Expand
Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
The reversible MAO-A inhibitors moclobemide and brofaromine, due to their well-documented safety characteristics, to their lack of anticholinergic-effects and to their good tolerability, will provide innovative tools for clarifying the role of MAO -A inhibitors in the treatment of endogenous and atypical depressive states. Expand
Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
The potentiation by moclobemide of the pressor response to oral TYR corresponds roughly to a fourfold left shift of the TYR dose-pressor response curve and is about 10 times less marked than after tranylcypromine. Expand
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
A systematic analysis of the tyramine content of current European food and beverage is reported and serves as a rational basis for providing advice to patients on moclobemide. Expand
Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen.
The conclusion of this study is that moclobemide should always be taken at the end of a meal, which is anyway the usual time for drug intake. Expand
A Case of Moclobemide Overdose
Overdose with moclobemide.